Details for Patent: 12,121,523

Which drugs does patent 12,121,523 protect, and when does it expire?

Patent 12,121,523 protects QELBREE and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 12,121,523

Title:	Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Abstract:	The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
Inventor(s):	Christopher D. Breder
Assignee:	Supernus Pharmaceuticals Inc
Application Number:	US17/896,774
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,121,523
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 12,121,523

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No	12,121,523					FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-002	Apr 2, 2021		RX	Yes	No	12,121,523					FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-003	Apr 2, 2021		RX	Yes	Yes	12,121,523					FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

International Family Members for US Patent 12,121,523

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2735934
European Patent Office	2341912
Spain	2459322